MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Core Insights - MIRA Pharmaceuticals has demonstrated that oral Mira-55 fully normalizes pain and significantly reduces inflammation, which supports its Investigational New Drug (IND) plans [1] - The findings reinforce MIRA's competitive position in the $70 billion non-opioid pain market [1] Company Summary - MIRA Pharmaceuticals, Inc. is focused on developing non-opioid pain management solutions, with recent findings highlighting the efficacy of its product, Mira-55 [1] - The company is advancing its plans for regulatory approval, indicating a strategic move towards commercialization in a lucrative market [1] Industry Summary - The non-opioid pain management market is valued at $70 billion, presenting significant opportunities for companies like MIRA Pharmaceuticals that are innovating in this space [1] - The shift towards non-opioid solutions is driven by the need for safer pain management alternatives, highlighting the relevance of MIRA's developments [1]